Antireflux surgery in the prevention of supra-esophageal can
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Gastroesophageal reflux disease (GERD), mainly characterized by heartburn or regurgitation, is a common condition in the Western world with an increasing prevalence. GERD is associated with an increased risk of adenocarcinoma of the esophagus, and possibly of supraesophageal cancers of the larynx, pharynx, and lung. GERD is typically treated with antireflux medication, mainly proton pump inhibitors, but an alternative is an antireflux surgery with fundoplication.

The present thesis aimed to assess outcomes of antireflux surgery with regards to supra-esophageal cancer risk and mortality by conducting multinational population-based cohort studies using the Nordic antireflux surgery cohort (NordASCo), which includes all adult individuals with a documented diagnosis of GERD or antireflux surgery procedure in the national patient registries.

Antireflux surgery is a safe treatment option in the treatment of gastroesophageal reflux disease. This surgery seems to reduce the risk of laryngeal and pharyngeal squamous cell carcinoma, and small cell carcinoma, and squamous cell carcinoma of the lung, and also decrease mortality in patients with gastroesophageal reflux disease.

The findings of this thesis contribute to new insights in the treatment effectiveness of antireflux surgery in individuals with more proximal reflux and regurgitation, in tumor etiology knowledge of the larynx, pharynx, and lung, and in the safety profile of antireflux surgery.

Karolinska Institutet
Source: openarchive.ki.se/xmlui/handle/10616/47484
Like
Comment
Share